First PROTAC Reaches FDA Filing After Phase 3 Win — A New Era in Drug Design
Arvinas' vepdegestrant becomes the first PROTAC to clear Phase 3 trials, targeting disease proteins for destruction rather than just blocking them.
415 articles in this topic
Arvinas' vepdegestrant becomes the first PROTAC to clear Phase 3 trials, targeting disease proteins for destruction rather than just blocking them.
Scientists engineer mammary organoids that secrete anticancer drugs while simultaneously regenerating functional breast tissue after surgery.
Japan's April 2026 revised guidelines now govern stem cell-based embryo models, marking a global regulatory milestone.
A biodegradable microneedle stent achieves sutureless intestinal anastomosis while releasing anti-inflammatory drugs triggered by local inflammation.
A precision CAR T cell therapy wipes out disease-driving myelofibrosis stem cells while sparing healthy ones — a potential cure candidate.
Researchers silenced nearly every expressed gene in human iPSCs, creating a landmark map of pluripotency's genetic architecture.
A new prime editing approach gives scientists precise genetic control over filamentous fungi, opening the door to novel bioactive compounds.
Researchers improve ADAR-based RNA editing precision using guide RNAs modeled on highly edited natural substrates.
Scientists uncover how corals repeatedly evolved a specialized organelle to house algal partners — by hijacking their own lysosomal machinery.
A newly identified pressure-sensing channel in liver cells may hold the key to unlocking faster, more complete liver repair.
Psychological stress impairs hematopoietic stem cells by suppressing brain regions, depleting gut microbiome-derived spermidine, and triggering ferroptosis.
A comprehensive review of inherited bone marrow failure, covering genetic causes, major syndromes, and the cytopenias that define them.